Femasys Partners with UNC Health to Expand FemaSeed Fertility Portfolio Across North Carolina
FEMY sits 42% above its 52-week low of $2.022 on light trading volume (0.3× avg).
Summary
Femasys announced a partnership with UNC Health, North Carolina's largest academic health system, to introduce its FemaSeed fertility portfolio—including FemVue, SpermVue, and FemaSeed Complete—across UNC Health OB/GYN practice locations. This is the first major health system adoption of the company's fertility products, following the commercial launch at ACOG in May and the recent $30M private placement that provided funding. The partnership expands access to fertility diagnostics and first-line treatment in community settings, potentially accelerating revenue growth for a company with Q2 sales of only $331,827. The deal validates the commercial strategy and could serve as a reference for other health systems. Watch for additional health system partnerships and Q3 revenue impact.
At the time of this announcement, FEMY was trading at $2.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $2.02 to $22.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.